RenalGuard Therapy™ is designed to reduce the toxic effects that contrast media can have on the kidneys, which may lead to a reduction in the incidence of Contrast-Induced Nephropathy (CIN) in at-risk patients. This therapy is based on existing published literature, including the PRINCE study¹, and initial pre-clinical work performed by PLC Medical Systems, Inc. which supports the theory that creating and maintaining a high urine output through the kidneys allows the body to rapidly eliminate contrast, reducing its toxic effects.

High urine rates may reduce the incidence of Contrast-Induced Nephropathy via a combination of known physiological factors, including:

• More rapid transit of contrast through the kidneys
• Less overall exposure to toxic contrast
• Reduced oxygen consumption in the medulla of the kidney

RenalGuard Therapy entails the use of a physician-prescribed loop diuretic which may induce the required high urine output. RenalGuard System is designed to measure urine output and replaces it in real-time with an equal volume of sterile saline. This matched fluid replacement aims to minimize the risk of over- or under-hydration which can lead to increased patient risks.

RenalGuard is currently being studied in Clinical Investigations to assess the safety and effectiveness in reducing the incidence of CIN. It is our hope that the use of RenalGuard will reduce the risk of CIN and associated long term morbidity and mortality due to exposure to contrast media, reducing hospital costs.

Clinical Investigations

1. Stevens, MA, McCullough, PA et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. JACC 1999;33:403-11